PUBLIC COMPANY
save$CAPRCAPRICOR THERAPEUTICS, INC.
$CAPR7.7750-13.13%San Diego, CA, USupdated 6h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
- phase2Open-label Extension of the HOPE-2 Trial
- phase2A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
- phase2Intravenous Infusion of CAP-1002 in Patients With COVID-19
- phase2HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
- phase2Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)
- phase2Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
🐶 Hiring Signal
News
- Capricor investor calls for change as company awaits decision on Duchenne candidateKaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and capital-preservation plan.” The biotech recently put all other pipeline work…biospace · 1mo ago
- UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharmaUniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by R…biospace · 2mo ago
- STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drugAhead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.stat · 2mo ago
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that